ArticleBritish journal of pharmacology2004
Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine.
Article in British journal of pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 28 citations in OpenAlex.
- Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review.Frontiers in neurology · 2017Review
- Critical role of calcitonin gene-related peptide receptors in cortical spreading depression.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Article
- Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks.CNS drug reviews · 2005Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neuropeptide calcitonin gene-related peptide (CGRP) is a potent vasodilator that is contained in and released from sensory nerves. CGRP has been implicated in migraine, and the nonpeptide CGRP antagonist BIBN4096BS has been shown to be effective in clinical trials in migraine. To date, it has been largely assumed that the CGRP antagonist is effective due to its ability to block vasodilator activity. Goadsby and co-workers present data that now suggest that CGRP antagonists may also block neuronal transmission in migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.